Does fixing a label typo need a supplement or just the annual report?

For an approved NDA or ANDA, an editorial or similar minor change in labeling goes in the annual report under 21 CFR 314.70(d). But a wrong word that changes a warning, direction or indication may not be minor, and labeling changes outside the listed categories generally need a supplement. Your regulatory team makes that call.

This page is general information, not legal or regulatory advice.

The three paths in 21 CFR 314.70

• Annual report (minor changes). Section 314.70(d) lists an editorial or similar minor change in labeling among the changes documented in the next annual report, filed under 21 CFR 314.81. It also covers changes to the product description or how-supplied information that don't change strength or dosage form.
• Changes-being-effected supplement. Section 314.70(c) lets certain labeling changes based on newly acquired information go ahead when the FDA receives the supplement, such as adding or strengthening a warning, contraindication, adverse reaction or a dosage instruction meant to make use safer.
• Prior approval supplement. Section 314.70(b) covers labeling changes outside those categories, which need approval before distribution.

What the FDA's guidance says about typos

The FDA's guidance Changes to an Approved NDA or ANDA (Revision 1, 2004) treats correcting spelling or typographical errors in previously submitted information as an editorial change. Its labeling examples for the annual report include editorial changes, and foreign-language versions with a certified translation and no content change.

Where a wrong word fits

A misspelling that leaves the meaning plain looks like the editorial case. A correctly spelled wrong word is harder. If the label says something other than the approved text, fixing it may just be restoring what was approved. If the approved text itself carried the wrong word, the fix changes the meaning of a warning or direction, and that's a judgment for regulatory, not a default to the annual report.

These rules cover approved applications. Products marketed without an approved application follow different rules, so check with your regulatory lead. For the full walk-through, see found a wrong word on a released label, and real cases on the case index.

Sources

• eCFR: 21 CFR 314.70
• FDA: Changes to an Approved NDA or ANDA

Last reviewed: October 14, 2026

More on contextual errors in FDA DailyMed labels.

Questions about wording on your own labels? Talk to us.

We scan freshly published FDA DailyMed labels every day and pull out these high-stakes wrong words.

Every Tuesday and Friday, a new case like this lands in your inbox if you subscribe.

Does a minor label typo need a supplement?

Under 21 CFR 314.70(d), an editorial or similar minor labeling change for an approved NDA or ANDA goes in the annual report. Whether a given fix is minor is your regulatory team's call.

Is a correctly spelled wrong word an editorial change?

Not automatically. If it changes the meaning of a warning, direction or indication, regulatory needs to decide the reporting path.

Which labeling changes can go ahead before the FDA approves them?

Under 21 CFR 314.70(c), certain changes based on new information, such as adding or strengthening a warning, can be made when the FDA receives the supplement.